OLD Mission Capital LLC Invests $203,000 in Celgene (CELG)

OLD Mission Capital LLC bought a new position in shares of Celgene (NASDAQ:CELG) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,941 shares of the biopharmaceutical company’s stock, valued at approximately $203,000.

Several other hedge funds have also made changes to their positions in the company. Arcadia Investment Management Corp MI lifted its stake in shares of Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 400 shares during the period. Robecosam AG acquired a new position in shares of Celgene during the third quarter valued at $114,000. Capital Bank & Trust Co lifted its stake in shares of Celgene by 166.8% during the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 517 shares during the period. Guidant Wealth Advisors acquired a new position in shares of Celgene during the third quarter valued at $119,000. Finally, Virtue Capital Management LLC acquired a new position in shares of Celgene during the fourth quarter valued at $101,000. Institutional investors own 78.53% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of Celgene stock opened at $90.54 on Tuesday. Celgene has a 1 year low of $84.25 and a 1 year high of $147.17. The stock has a market capitalization of $67,244.50, a price-to-earnings ratio of 13.24, a price-to-earnings-growth ratio of 0.60 and a beta of 1.48. The company has a quick ratio of 4.80, a current ratio of 4.99 and a debt-to-equity ratio of 2.29.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The company had revenue of $3.48 billion during the quarter, compared to the consensus estimate of $3.46 billion. During the same period in the prior year, the company earned $1.61 earnings per share. The company’s revenue for the quarter was up 16.9% compared to the same quarter last year. research analysts predict that Celgene will post 7.66 EPS for the current fiscal year.

Celgene declared that its board has initiated a share buyback program on Wednesday, February 14th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board believes its shares are undervalued.

Several equities analysts have recently issued reports on the company. Vetr lowered Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price target on the stock. in a research note on Monday, December 18th. Citigroup reaffirmed a “hold” rating on shares of Celgene in a research note on Friday, December 22nd. Credit Suisse Group set a $123.00 price target on Celgene and gave the company a “buy” rating in a research note on Friday, December 22nd. Stifel Nicolaus cut their price target on Celgene from $149.00 to $130.00 and set a “buy” rating on the stock in a research note on Friday, December 22nd. Finally, Cantor Fitzgerald set a $112.00 price target on Celgene and gave the company a “hold” rating in a research note on Thursday, December 21st. Four analysts have rated the stock with a sell rating, twelve have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $126.95.

In related news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $95.99, for a total transaction of $887,907.50. Following the completion of the transaction, the director now directly owns 94,801 shares in the company, valued at $9,099,947.99. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ernest Mario sold 13,370 shares of the stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $94.49, for a total value of $1,263,331.30. The disclosure for this sale can be found here. Insiders sold 41,120 shares of company stock valued at $3,879,509 over the last 90 days. Corporate insiders own 0.95% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “OLD Mission Capital LLC Invests $203,000 in Celgene (CELG)” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.chaffeybreeze.com/2018/04/17/old-mission-capital-llc-invests-203000-in-celgene-celg.html.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply